title: Tissue-selective therapy of cancer.
abstract: Instead of exploiting the differences between normal and cancer cells, seemingly unrelated anticancer modalities (from immunotherapy to hormones) exploit (a). the differences between various normal tissues and (b). tissue-specific similarities of normal and cancer cells. Although these therapies are successfully used for years to treat leukaemia and cancer, their unifying principles have never been explicitly formulated: namely, they are aimed at differentiated cells and normal tissues and target both normal and cancer cells in a tissue-specific manner. Whereas tiny differences between cancer and normal cells have yet to be successfully exploited for selective anticancer therapy, numerous tissue-specific differences (e.g. differences between melanocytes, prostate, thyroid and breast cells) provide a means to attack selectively that exact tissue that produced cancer. Despite inherent limitations, such as fostering resistance and dedifferentiation, tissue-selective therapy have enormous potentials to control cancer.
authors.affiliation: Department of Medicine, New York Medical College, Valhalla, NY 10595, USA. M-Blagosklonny@NYMC.EDU
authors.forename: M V
authors.initials: MV
authors.lastname: Blagosklonny
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D009928:Organ Specificity
chemical_list: D000970:Antineoplastic Agents